Aspira Womens Health Inc AWH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AWH is a good fit for your portfolio.
News
-
Aspira Women’s Health Announces Preliminary Second Quarter 2024 OvaSuite Product Volume and Highlights
-
Aspira Women’s Health Announces Closing of $1.9 Million Private Placement Equity Financing
-
Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing
-
Aspira Women’s Health Provides Commercial, Reimbursement and Cash Guidance Updates
-
Aspira Women’s Health to Present at the A.G.P. Healthcare Showcase on May 21
-
Aspira Women’s Health Reports First Quarter 2024 Financial Results
-
UPDATE — Aspira Women’s Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
-
Aspira Women’s Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.41–1.54
- 52-Week Range
- $0.86–6.75
- Bid/Ask
- $1.23 / $1.55
- Market Cap
- $21.27 Mil
- Volume/Avg
- 45,083 / 111,997
Key Statistics
- Price/Earnings (Normalized)
- 0.05
- Price/Sales
- 1.68
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 64
- Website
- https://www.aspirawh.com
Valuation
|
Metric
|
AWH
|
|---|---|
Price/Earnings (Normalized) | 0.05 |
Price/Book Value | — |
Price/Sales | 1.68 |
Price/Cash Flow | — |
Price/Earnings
AWH
Financial Strength
|
Metric
|
AWH
|
|---|---|
Quick Ratio | 0.93 |
Current Ratio | 1.16 |
Interest Coverage | — |
Quick Ratio
AWH
Profitability
|
Metric
|
AWH
|
|---|---|
Return on Assets (Normalized) | −181.04% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −778.41% |
Return on Assets
AWH
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Pscfgqzqv | Syv | $231.8 Bil | |||
| Danaher Corp
DHR
| Fgbncspskz | Rwrzrtn | $197.8 Bil | |||
| IQVIA Holdings Inc
IQV
| Mnpphgt | Hqwptw | $43.7 Bil | |||
| Agilent Technologies Inc
A
| Rlzlhcpktf | Fdsq | $40.1 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Jdgttncr | Snxhgpv | $38.8 Bil | |||
| Mettler-Toledo International Inc
MTD
| Jnvjrhncjh | Qhzzf | $31.0 Bil | |||
| Icon PLC
ICLR
| Hwgswhvb | Fntyg | $26.8 Bil | |||
| Illumina Inc
ILMN
| Pkpckykx | Jxcmxf | $19.2 Bil | |||
| Waters Corp
WAT
| Jbqbzzfgcs | Rbnx | $18.9 Bil | |||
| Labcorp Holdings Inc
LH
| Vwhtnfqdg | Jqvlyjn | $17.8 Bil |